Abstract
During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Current Drug Safety
Title:Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Volume: 11 Issue: 1
Author(s): E. Molinelli, A. Campanati, G. Ganzetti and A. Offidani
Affiliation:
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Abstract: During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Export Options
About this article
Cite this article as:
Molinelli E., Campanati A., Ganzetti G. and Offidani A., Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115127
DOI https://dx.doi.org/10.2174/1574886310666151014115127 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Current Nutrition & Food Science Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Fathoming the Role of mTOR in Diabetes Mellitus and its Complications
Current Molecular Pharmacology Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review
Mini-Reviews in Medicinal Chemistry Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Nutrigenomics and Personalized Diet: What are the Anticipated Impacts for Research on Chronic Diseases and Public Health?
Current Pharmacogenomics and Personalized Medicine In Silico Drug Repositioning for Chagas Disease
Current Medicinal Chemistry Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions
Current Vascular Pharmacology Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Incorporating Insulin Growth Factor-1 into Regenerative and Personalized Medicine for Cardiovascular Disease: A Systematic Review
Current Stem Cell Research & Therapy Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Current Molecular Medicine The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Nano-zinc Coordination with the Ligands of Carboplatin, Oxaliplatin and Nedaplatin. Synthesis, Characterization and Biological Properties
Letters in Organic Chemistry